

Zhi-Yong Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8394838/publications.pdf>

Version: 2024-02-01

50
papers

2,113
citations

331259

21
h-index

233125

45
g-index

50
all docs

50
docs citations

50
times ranked

3932
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of genomic alterations in oesophageal squamous cell cancer. <i>Nature</i> , 2014, 509, 91-95.	13.7	903
2	Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma. <i>Gastroenterology</i> , 2018, 154, 2137-2151.e1.	0.6	165
3	Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma. <i>American Journal of Gastroenterology</i> , 2014, 109, 36-45.	0.2	99
4	Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. <i>Nature Communications</i> , 2021, 12, 4961.	5.8	63
5	ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2014, 5, 8569-8582.	0.8	54
6	Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. <i>Cell Reports</i> , 2020, 31, 107753.	2.9	52
7	SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. <i>Human Pathology</i> , 2016, 52, 153-163.	1.1	48
8	LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion. <i>Cancer Research</i> , 2019, 79, 4951-4964.	0.4	47
9	The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3 ^{Î²} in Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 691-703.	3.2	46
10	Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma. <i>Cancer Communications</i> , 2018, 38, 1-13.	3.7	44
11	A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 5435-5448.	0.8	40
12	SLC52A3 expression is activated by NF-Î²B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2643-2661.	2.4	38
13	A Molecular Prognostic Model Predicts Esophageal Squamous Cell Carcinoma Prognosis. <i>PLoS ONE</i> , 2014, 9, e106007.	1.1	30
14	A systematic analysis of human lipocalin family and its expression in esophageal carcinoma. <i>Scientific Reports</i> , 2015, 5, 12010.	1.6	28
15	A three-gene signature from protein-protein interaction network of LOXL2 and actin-related proteins for esophageal squamous cell carcinoma prognosis. <i>Cancer Medicine</i> , 2017, 6, 1707-1719.	1.3	28
16	Systematic Proteome and Lysine Succinylome Analysis Reveals Enhanced Cell Migration by Hyposuccinylation in Esophageal Squamous Cell Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100053.	2.5	28
17	L1CAM drives oncogenicity in esophageal squamous cell carcinoma by stimulation of ezrin transcription. <i>Journal of Molecular Medicine</i> , 2017, 95, 1355-1368.	1.7	27
18	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). <i>Clinical Cancer Research</i> , 2022, 28, 637-645.	3.2	27

#	ARTICLE	IF	CITATIONS
19	STAT3 ^{hi} disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 522, 171-183.	3.2	26
20	Integrin $\alpha 5$ promotes tumor progression and is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. <i>Human Pathology</i> , 2016, 48, 69-75.	1.1	22
21	HiFreSP: A novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures. <i>Briefings in Bioinformatics</i> , 2020, 21, 1411-1424.	3.2	21
22	Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative , early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. <i>International Journal of Cancer</i> , 2022, 150, 654-662.	2.3	21
23	Plasma apolipoprotein A1 levels at diagnosis are independent prognostic factors in invasive ductal breast cancer. <i>Discovery Medicine</i> , 2017, 23, 247-258.	0.5	20
24	Non-coding RNAs rewire cancer metabolism networks. <i>Seminars in Cancer Biology</i> , 2021, 75, 116-126.	4.3	17
25	Identification of key genes by integrating DNA methylation and next-generation transcriptome sequencing for esophageal squamous cell carcinoma. <i>Aging</i> , 2020, 12, 1332-1365.	1.4	17
26	Overexpression of Stathmin $\alpha 2$ correlates with poor prognosis and promotes cell migration and proliferation in oesophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2017, 38, 3608-3618.	1.2	16
27	P300/CBP-associated factor (PCAF)-mediated acetylation of Fascin at lysine 471 inhibits its actin-binding activity and tumor metastasis in esophageal cancer. <i>Cancer Communications</i> , 2021, 41, 1398-1416.	3.7	16
28	The prognostic implications of microvascular density and lymphatic vessel density in esophageal squamous cell carcinoma: Comparative analysis between the traditional whole sections and the tissue microarray. <i>Acta Histochemica</i> , 2014, 116, 646-653.	0.9	15
29	Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour. <i>EBioMedicine</i> , 2020, 51, 102566.	2.7	15
30	Overexpression of GRB2 is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3132-40.	0.5	14
31	Low EphA7 Expression Correlated with Lymph Node Metastasis and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma. <i>Acta Histochemica Et Cytochemica</i> , 2015, 48, 75-81.	0.8	13
32	Plasma Riboflavin Level is Associated with Risk, Relapse, and Survival of Esophageal Squamous Cell Carcinoma. <i>Nutrition and Cancer</i> , 2017, 69, 21-28.	0.9	13
33	A decision tree-based combination of ezrin-interacting proteins to estimate the prognostic risk of patients with esophageal squamous cell carcinoma. <i>Human Pathology</i> , 2017, 66, 115-125.	1.1	12
34	Prognostic Role of Nodal Skip Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 6341-6352.	0.7	11
35	Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	11
36	A four actin-binding protein signature model for poor prognosis of patients with esophageal squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 5950-9.	0.5	10

#	ARTICLE	IF	CITATIONS
37	Altered expression and localization of desmoglein 3 in esophageal squamous cell carcinoma. <i>Acta Histochemica</i> , 2014, 116, 803-809.	0.9	9
38	Lymph Node Station-Based Nodal Staging System for Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4045-4052.	0.7	9
39	The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases. <i>Epigenomics</i> , 2019, 11, 1237-1250.	1.0	7
40	Prognostic significance of perigastric lymph nodes metastases on survival in patients with thoracic esophageal cancer. <i>Ecological Management and Restoration</i> , 2010, 23, 40-45.	0.2	5
41	Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study. <i>Medical Science Monitor</i> , 2019, 25, 9167-9178.	0.5	5
42	The expression of β -catenin in esophageal squamous cell carcinoma and its correlations with prognosis of patients. <i>Human Pathology</i> , 2014, 45, 2014-2022.	1.1	4
43	Role of Integrin α 21 in the progression and chemo-resistance of esophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2022, 13, 2074-2085.	1.2	4
44	Fascin and esophageal squamous cell carcinoma. <i>Precision Radiation Oncology</i> , 2017, 1, 82-87.	0.4	3
45	Decreased plasma riboflavin is associated with poor prognosis, invasion, and metastasis in esophageal squamous cell carcinoma. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 1149-1156.	1.3	2
46	Prognostic impact of lymph node harvest for patients with node-negative esophageal squamous cell carcinoma: a large-scale multicenter study. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1951-1962.	0.6	2
47	CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3301-3310.	0.5	2
48	The Least Nodal Disease Burden Defines the Minimum Number of Nodes Retrieved for Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 764227.	1.3	2
49	Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis. <i>Breast Care</i> , 2021, 16, 156-162.	0.8	1
50	The analyses of SRCR genes based on protein-protein interaction network in esophageal squamous cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 2683-2705.	0.0	1